Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors

Clinical Nuclear Medicine

Volumn 37, Issue 2, 2012, Pages 158-163

  Tripathi, Madhavi ^a   Sharma, Rajnish ^a   Varshney, Raunak ^a   Jaimini, Abhinav ^a   Jain, Jyotika ^b   Souza, Maria M D ^a   Bal, Jaspriya ^a   Pandey, Santosh ^a   Kumar, Nitin ^a   Mishra, Anil K ^a   Mondal, Anupam ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b UCMS AND GTB HOSPITAL   (India)

Author keywords

C 11 methionine; F 18 FDG; GBM; gliomas; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

ADOLESCENT; ADULT; ARTICLE; BRAIN CORTEX; CANCER RECURRENCE; CANCER SURGERY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PHYSICIAN; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DEMOGRAPHY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; YOUNG ADULT;

EID: 84855774309     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318238f51a     Document Type: Article

References (23)

1. Schober O, Duden C, Meyer GJ, et al. Non-selective transport of C-11- methyl-L and D-methionine into a malignant glioma. Eur J Nucl Med. 1987;13:103-105 (Pubitemid 17091386)
2. Kaschten B, Stevenaert A, Sadzot B, et al. Pre-operative evaluation of 54 gliomas by PET with F-18 FDG and/or C-11 Methionine. J Nucl Med. 1998;39:778-785 (Pubitemid 28216722)
3. Derlon JM, Bourdet C, Bustany P, et al. C-11-methionine uptake in gliomas. Neurosurgery. 1989;25:720-728
4. Ogawa T, Kanno I, Shishido F, et al. Clinical value of PET with F-18- flurodeoxyglucose and L-methyl-C11-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol. 1991;32:197-202
5. Laere VL, Ceyssens S, Calenbergh FV, et al. Direct comparison of f-18 FDG and C-11 methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39-51 (Pubitemid 40142777)
6. Chung JK, Kim YK, Kim SK, et al. Usefulness of C-11 methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on F-18 FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176-182 (Pubitemid 44763148)
7. De Witte O, Goldberg I, Wilker D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95:746-750 (Pubitemid 33043345)
8. Kim S, Chung JK, Im SH, et al. C-11 methionine PET as a prognostic marker in patients with glioma: comparison with F-18 FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:52-59 (Pubitemid 40142778)
9. Ericson K, Lilja A, Bergstrom M, et al. PET with (C-11 methyl)-L-methionine,C-11 Dglucose, and Ga-68 EDTA in supratentorial tumors. J Comput Assist Tomogr. 1985;9:683-689
10. Uda T, Tsuyuguchi N, Terakawa Y, et al. Evaluation of the accumulation of C-11 methionine with standardized uptake value in the normal brain. J Nucl Med. 2010;51:219-222
11. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of C-11 methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694-699 (Pubitemid 351717532)
12. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000;41:1861-1867
13. Barker FG, Chang SM, Valk PE, et al. 18-Flurodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer. 1997;79:115-126 (Pubitemid 26425516)
14. Chao ST, Suh JH, Raja S, et al. Sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191-197 (Pubitemid 32520674)
15. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 flurodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52
16. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-18F fluoroethyl)-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33:287-294
17. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-18F fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40: 205-212 (Pubitemid 29044193)
18. Weber WA, Wester HJ, Grosu AL, et al. O-(2-18F fluoroethyl)-L-tyrosine and L-methyl-11C methionine uptake in brain tumors: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549 (Pubitemid 30262620)
19. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of flurotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501-508 (Pubitemid 36776519)
20. Pauleit D, Floeth F, Hamacher K, et al. O-(2-18F Fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687 (Pubitemid 40380202)
21. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18Ffluoroethyl)- L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519-527 (Pubitemid 47571405)
22. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95: 87-93
23. Rachinger W, Goetz C, Pöpperl G, et al. Positron emission tomography with O-(2-18F fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505-511 (Pubitemid 41254459)